1,618 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B Downtrend
Article Searches
Putnam Fl Investment Management Co Buys Amgen Inc, CVS Health Corp, Cisco Systems Inc, Sells ... http://www.gurufocus.com/news/821173/putnam-fl-investment-management-co-buys-amgen-inc-cvs-health-corp-cisco-systems-inc-sells-aetna-inc-invesco-qqq-trust-series-1-facebook-inc Feb 22, 2019 - Putnam Fl Investment Management Co Buys Amgen Inc, CVS Health Corp, Cisco Systems Inc, Sells Aetna Inc, Invesco QQQ Trust Series 1, Facebook Inc, Stocks: AMGN,CVS,CSCO,IEFA,DRI,BAC,MAS,PBCT,MDT,XLE,AJG,BH, release date:Feb 22, 2019
Amgen Starts Phase III Enrollment for Heart Failure Drug http://www.zacks.com/stock/news/356653/amgen-starts-phase-iii-enrollment-for-heart-failure-drug?cid=CS-ZC-FT-356653 Feb 22, 2019 - Amgen (AMGN) and partners started enrollment for the second phase III study of omecamtiv mecarbil, which is being developed for the potential treatment of heart failure with reduced ejection fraction.
The Zacks Analyst Blog Highlights: Walmart, Amgen, Honda, TransCanada and TransUnion http://www.zacks.com/stock/news/355997/the-zacks-analyst-blog-highlights-walmart-amgen-honda-transcanada-and-transunion?cid=CS-ZC-FT-355997 Feb 21, 2019 - The Zacks Analyst Blog Highlights: Walmart, Amgen, Honda, TransCanada and TransUnion
Merck Gets Priority Review for Keytruda in Third-Line SCLC http://www.zacks.com/stock/news/355982/merck-gets-priority-review-for-keytruda-in-third-line-sclc?cid=CS-ZC-FT-355982 Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Top Analyst Reports for Walmart, Amgen and Honda http://www.zacks.com/research-daily/215092/top-analyst-reports-for-walmart-amgen-and-honda?cid=CS-ZC-FT-215092 Feb 20, 2019 - Top Analyst Reports for Walmart, Amgen and Honda
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study http://www.zacks.com/stock/news/355533/mercks-keytruda-fails-to-meet-endpoint-in-liver-cancer-study?cid=CS-ZC-FT-355533 Feb 20, 2019 - Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review http://www.zacks.com/stock/news/355489/roches-rhhby-bla-for-lymphoma-drug-gets-priority-review?cid=CS-ZC-FT-355489 Feb 19, 2019 - The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.
What Are The Highest Quality Dividend Growth Stocks? https://seekingalpha.com/article/4242014-highest-quality-dividend-growth-stocks?source=feed Feb 19, 2019 - Many dividend growth investors seek the highest-quality companies.Independent data providers such as S&P, Morningstar, and Simply Safe Dividends offer rankings of quality factors.A simple scoring syst
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer http://www.zacks.com/stock/news/355193/merck-gets-priority-review-for-keytruda-combo-in-kidney-cancer?cid=CS-ZC-FT-355193 Feb 18, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Regeneron and Sanofi prevail in review of Amgen's IL-4 receptor patent https://seekingalpha.com/news/3434167-regeneron-sanofi-prevail-review-amgens-ilminus-4-receptor-patent?source=feed_news_all Feb 16, 2019 - Regeneron Pharmaceuticals (NASDAQ:REGN) and development partner Sanofi (NASDAQ:SNY) announce that the USPTO has invalidated 17 claims as obvious of U.S. Patent No. 8,679,487 owned by Amgen's (NASDAQ:A

Pages: 123456...162

Page 1>

Related Companies

Name Exchange Price Mkt Cap
GILD Gilead Sciences, Inc. NASDAQ $72.78 $94.35B
BIIB Biogen Inc. NASDAQ $334.44 $67.37B
SGEN Seattle Genetics, Inc. NASDAQ $76.15 $12.09B
NBIX Neurocrine Biosciences, Inc. NASDAQ $117.38 $10.62B
QGEN Qiagen N.V. NASDAQ $37.42 $8.5B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)
DeepLinks for Amgen
AMGN - Google Finance https://www.google.com/finance?q=AMGN Industry related info and international coverage Summary News
AMGN - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=AMGN Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options